<Supporting information for online publication only

Table S2. Quality Assessment and Jadad Score of Included Trials

Source [Reference No.] / Allocation
Method / Blinding Methods / Were withdrawals and dropouts fully described / analyzed? / Statistical Methods / Inclusion / Exclusion criteria / Method of assessing adverse effects / Jadad Score
Tolterodine
Jonas et al, 1997 [1]
Tolterodine / Unclear / Unclear / Partially described / analyzed / Inadequately described / Clearly described / Unclear / 6
Malone-Lee et al, 2001 [2]
Tolterodine / Unclear / Adequate / Partially described / analyzed / Inadequately described / Clearly described / Unclear / 7
Jacquetin et al, 2001 [3]
Tolterodine / Unclear / Unclear / Yes / Clearly described / Clearly described / Unclear / 8
Chapple et al, 2004b [4]
Tolterodine / Unclear / Unclear / Yes / Clearly described / Clearly described / Unclear / 8
Pharmacia and Upjohn Phase III [Studies 94-OATA-008, -009, -010] [5, 6]
Tolterodine / Unclear / Adequate / Partially described / analyzed / Clearly described / Clearly described / Unclear / 8
Phase III [Study 94-TOCR-007 Vankerrebroeck et al, 2001] [7]
Tolterodine / Unclear / Adequate / Partially described / analyzed / Clearly described / Clearly described / Unclear / 8
Homma et al, 2003 [8]
Tolterodine / Adequate / Adequate / Yes / Clearly described / Clearly described / Unclear / 10
Kaplan et al, 2006 [9]
Tolterodine / Adequate / Adequate / Yes / Clearly described / Clearly described / Unclear / 10
Khullar et al, 2004 [10]
Tolterodine / Adequate / Adequate / Yes / Clearly described / Clearly described / Unclear / 10
Rackley et al, 2006 [11]
Tolterodine / Unclear / Unclear / Partially described / analyzed / Clearly described / Clearly described / Unclear / 7
Darifenacin
Lipton et al, 2005 [12]
Darifenacin / Adequate / Adequate / Yes / Clearly described / Clearly described / Unclear / 10
Novartis
Phase III (Study A1371001) [13] / NA / NA / NA / NA / NA / NA / NA
Phase III (Study A1371002, Haab et al, 2004) [13, 14]
Darifenacin / Adequate / Unclear / Partially described / analyzed / Clearly described / Clearly described / Questionnaire / 9
Phase III (Study A1371041, Hill et al, 2006) [13, 15]
Darifenacin / Unclear / Unclear / Yes / Clearly described / Clearly described / Unclear / 8
Phase III (Study A1371047, Steers et al 2005) [13, 16]
Darifenacin / Unclear / Unclear / Partially described / analyzed / Clearly described / Clearly described / Unclear / 7
Chapple et al, 2007
Darifenacin [17] / Unclear / Adequate / Partially described / analyzed / Clearly described / Clearly described / Unclear / 8
Fesoterodine
Pfizer, Inc
Phase III (Study SP583, Chapple et al, 2007) [18, 19]
Fesoterodine / Unclear / Adequate / Yes / Clearly described / Clearly described / Unclear / 9
Phase III (Study SP584, Nitti et al, 2007) [18, 20]
Fesoterodine / Unclear / Unclear / Partially described / analyzed / Clearly descrzibed / Clearly described / Unclear / 7
Herschorn, et al, 2009
Fesoterodine [21] / Adequate / Adequate / Yes / Clearly described / Clearly described / Unclear / 10
Oxybutynin
Szonyi et al, 1995 [22]
Oxybutynin / Unclear / Unclear / Partially described / analyzed / Clearly described / Clearly described / Questionnaire / 8
Watson Pharma Phase III (Oxytrol study O00011, Dmochowski et al, 2003) [23]
Oxybutynin / Unclear / Unclear / Yes / Clearly described / Unclear / Unclear / 7
Staskin et al, 2009 [24]
Oxybutynin / Unclear / Adequate / Yes / Clearly described / Clearly described / Unclear / 9
Lackner et al, 2008 [25]
Oxybutynin / Adequate / Adequate / Partially described / analyzed / Clearly described / Clearly described / Clinician/patient questionnaire with severity rating / 10
Thuroff et al, 1991 [26]
Oxybutynin / Adequate / Adequate / Yes / Inadequately described / Clearly described / Unclear / 8
Tapp et al, 1990 [27]
Oxybutynin / Adequate / Adequate / Partially described / analyzed / Inadequately described / Clearly described / Unclear / 8
Zinner et al, 2005 [28]
Oxybutynin / Unclear / Unclear / Partially described / analyzed / Clearly described / Clearly described / Unclear / 7
Trospium
Indevus Pharmaceutical, Inc.
Phase III (Study IP631-003, Zinner et al, 2004) [29, 30]
Trospium / Unclear / Unclear / Yes / Clearly described / Clearly described / Unclear / 8
Phase III (Study IP631-005, Rudy et al, 2006) [30, 31]
Trospium / Unclear / Unclear / Yes / Clearly described / Clearly described / Unclear / 8
Phase III (Study IP631-018, Staskin, et al, 2007) [32, 33]
Trospium / Adequate / Unclear / Partially described / analyzed / Clearly described / Clearly described / Unclear / 8
Phase III (Study IP631-022) [33, 34]
Trospium / Adequate / Unclear / Partially described / analyzed / Clearly described / Clearly described / Unclear / 8
Solifenacin
Yamanouchi Pharma America, Inc Phase III (Study 905-CL-013) [35]
Solifenacin / Unclear / Unclear / Partially described / analyzed / Clearly described / Clearly described / Unclear / 7
Phase III (Study 905-CL-014) [35]
Solifenacin / Unclear / Unclear / Partially described / analyzed / Clearly described / Clearly described / Unclear / 7
Phase III (Study 905-CL-015, Chapple et al, 2004b) [4, 35]
Solifenacin / Unclear / Unclear / Partially described / analyzed / Clearly described / Clearly described / Unclear / 7
Phase III (Study 905-CL-018) [35, 36]
Solifenacin / Unclear / Unclear / Yes / Clearly described / Clearly described / Unclear / 8
Yamaguchi et al, 2007 [37]
Solifenacin / Unclear / Unclear / Partially described / analyzed / Clearly described / Clearly described / Unclear / 7
Cardozo et al, 2008 [38] / Unclear / Adequate / Yes / Clearly described / Clearly described / Unclear / 9
Karram et al, 2009 [39] / Unclear / Unclear / Yes / Clearly described / Clearly described / Unclear / 8

NA = not available from source